Related by context. All words. (Click for frequent words.) 73 Ph + CML 71 lymphoid blast 70 chronic myeloid leukemia CML 69 imatinib resistant 66 cytogenetic response 66 CCyR 66 Gleevec resistant 66 dasatinib Sprycel ® 66 T#I mutation 65 leukemia AML 65 cytogenetic responses 65 chronic myelogenous leukemia CML 65 relapsed refractory multiple myeloma 65 BCR ABL mutation 64 MCyR 64 imatinib Gleevec ® 64 diagnosed Ph + 64 CML CP 64 refractory chronic myeloid 64 myelodysplastic syndrome MDS 64 erlotinib Tarceva ® 63 myelodysplastic myeloproliferative diseases 63 docetaxel chemotherapy 63 dasatinib 63 autoantibody positive 63 heavily pretreated 63 nilotinib 63 leukemia CLL 63 leukemia CML 63 metastatic malignant 63 chronic myeloid 62 stage IIIB 62 metastatic GIST 62 hypereosinophilic syndrome 62 chronic eosinophilic leukemia 62 imatinib 62 DMARD therapy 62 receptor tyrosine kinase inhibitor 62 refractory NSCLC 62 cell lymphoma CTCL 62 chlorambucil 62 bevacizumab Avastin ® 62 myelodysplastic syndromes 62 refractory AML 62 imatinib Gleevec 62 leukemia ALL 62 dasatinib Sprycel 62 imatinib therapy 62 serologically active systemic lupus 62 TTF Therapy 61 Kit CD# positive 61 lymphoid malignancies 61 tyrosine kinase inhibitors TKIs 61 antibody MAb 61 SPRYCEL ® 61 recurrent NSCLC 61 4mg/kg 61 disease modifying antirheumatic 61 Myelofibrosis 61 standard chemotherapy regimens 61 epithelial tumors 61 cetuximab Erbitux ® 61 papillary renal cell carcinoma 61 achieve sustained virologic 61 FOLFIRI 61 KRAS mutations occur 61 recurrent glioblastoma multiforme 61 TKIs 61 refractory cutaneous T 61 refractory chronic lymphocytic 61 HES CEL 61 drugs DMARDs 61 ara C 61 irinotecan containing 61 irinotecan chemotherapy 61 Bcr Abl T#I mutation 61 metastatic renal cell carcinoma 61 Ph + acute lymphoblastic 61 standard chemotherapy regimen 61 systemic anaplastic large 61 dacarbazine 61 non metastatic osteosarcoma 61 Pegasys ® 61 HER2 positive metastatic breast 61 sunitinib Sutent ® 60 gastrointestinal stromal tumors GIST 60 nilotinib Tasigna ® 60 myeloid 60 FOLFOX 60 refractory CML 60 Omacetaxine 60 ponatinib 60 chronic lymphocytic leukemia CLL 60 ACTEMRA TM 60 relapsed refractory 60 hypercalcemia 60 PEGylated Fab fragment 60 complete remissions 60 glioblastoma multiforme GBM 60 Cutaneous T 60 cutaneous T 60 eosinophilic asthma 60 myelofibrosis 60 CHOP chemotherapy 60 Fludarabine 60 fludarabine 60 DOXIL 60 partial remissions 60 acute myeloid leukemia AML 60 alfa 2a 60 HGS ETR1 60 metastatic malignant melanoma 60 FluCAM arm 60 unresectable 60 imatinib mesylate Gleevec 60 stage IIIb IV 60 polycythemia vera PV 60 acute myeloid 60 DMARD 60 adriamycin 60 lupus nephritis 60 cutaneous T cell 60 Diffuse Large B 60 histone deacetylase HDAC inhibitor 60 progressive PsA 60 estramustine 60 temsirolimus Torisel ® 60 cisplatin gemcitabine 60 achieved CCyR 60 ribavirin therapy 60 gastrointestinal stromal tumor GIST 59 atypical Hemolytic Uremic Syndrome 59 indolent NHL 59 imatinib mesylate 59 alkylating agent 59 bendamustine 59 HCV genotypes 59 tyrosine kinase inhibitors 59 achieved ACR# 59 plus gemcitabine 59 Irinotecan 59 Bezielle 59 metastatic CRC 59 certolizumab 59 Fludara 59 8mg/kg 59 relapsed CLL 59 myeloproliferative disorders 59 ribavirin RBV 59 remission induction 59 tumors GIST 59 mcg kg REBETOL 59 sorafenib Nexavar ® 59 metastatic renal cell 59 MGd 59 Cloretazine 59 tyrosine kinase inhibitor TKI 59 basal cell carcinoma BCC 59 relapsed MM 59 previously untreated follicular 59 Chronic Myeloid Leukemia 59 neutropenia dehydration dyspnea 59 myeloproliferative diseases 59 gastrointestinal stromal tumors 59 myelofibrosis polycythemia vera 59 refractory metastatic 59 FOLFOX6 59 purpura ITP 59 gemcitabine Gemzar ® 59 fallopian tube carcinoma 59 chemotherapy regimens 59 severe oral mucositis 59 #mg/m# [001] 59 hematologic toxicity 59 tumor lysis syndrome 59 lenalidomide Revlimid R 59 resistant ovarian cancer 59 superficial bladder cancer 59 metastatic pancreatic 59 immunomodulatory therapy 59 metastatic castration resistant 59 biologic therapy 59 receiving highly emetogenic 59 vandetanib 59 cetuximab Erbitux R 59 PKC# 59 gemcitabine carboplatin 59 pyrexia mucositis sepsis febrile 59 plus methotrexate 59 primary hypercholesterolemia 59 haematologic 59 complement inhibitor eculizumab 59 Pharmacokinetics PK 59 sunitinib malate 59 weekly subcutaneous injections 59 platinum refractory 59 neuroendocrine cancers 58 daunorubicin 58 idarubicin 58 painful diabetic neuropathy 58 alvespimycin 58 forodesine 58 novel VDA molecule 58 evaluating tivozanib 58 crizotinib PF # 58 gefitinib Iressa 58 lintuzumab SGN 58 CYT# potent vascular disrupting 58 motesanib 58 liposomal formulation 58 TNF antagonist 58 gemcitabine chemotherapy 58 EGFR HER2 58 anthracycline taxane 58 advanced metastatic renal 58 blastic phase 58 recurrent metastatic 58 Response Evaluation Criteria 58 limiting toxicity 58 Amrubicin 58 acute GvHD 58 HGS ETR1 mapatumumab 58 Vidaza ® 58 B CLL 58 complete cytogenetic response 58 Cell Lymphoma 58 cisplatin chemotherapy 58 xanthine oxidase inhibitor 58 FluCAM 58 Relapsed Refractory 58 Ribavirin causes 58 PEGylated interferon beta 1a 58 unstable angina UA 58 carboplatin paclitaxel 58 naïve HCV 58 Elotuzumab 58 pancreatic NET 58 K ras mutations 58 KRAS wild 58 alkylating agents 58 Chronic Myelogenous Leukemia 58 #mg/m# [002] 58 Folfox 58 non squamous NSCLC 58 nab paclitaxel 58 bevacizumab Avastin R 58 chronic immune thrombocytopenic 58 FOLFOX6 chemotherapy regimen 58 ThermoDox R 58 essential thrombocythemia ET 58 5 fluorouracil 58 systemic lupus erythematosus 58 mCRC patients 58 plus dexamethasone 58 carboplatin 58 orally administered inhibitor 58 Philadelphia Chromosome Positive 58 metastatic castrate resistant 58 familial amyloidotic polyneuropathy FAP 58 telaprevir dosed 58 docetaxel Taxotere ® 58 panitumumab Vectibix 58 BCR ABL 58 fallopian tube cancers 58 HER2 overexpression 58 ritonavir boosted 58 essential thrombocythemia 58 castrate resistant prostate cancer 58 advanced unresectable 58 follicular lymphoma FL 58 febrile neutropenia 58 metastatic kidney 58 adverse cytogenetics 58 Xanafide 58 CIMZIA ™ 58 Soft Tissue Sarcoma 58 pegylated interferon alfa 2a 58 Randomized Phase 58 EGFR TKI 58 melphalan prednisone 58 visilizumab 58 atopic asthma 58 mg/m2 dose 58 CIMZIA TM 58 CD4 monoclonal antibody 57 sunitinib 57 Metastatic Colorectal Cancer 57 lymphoma CTCL 57 DMARDS 57 leukemia APL 57 situ CIS 57 Crohn disease CD 57 tanespimycin 57 prior chemotherapy regimens 57 Hsp# Inhibitor 57 TORISEL 57 kidney urologic 57 ceftazidime 57 demonstrated antitumor activity 57 HCV RESPOND 2 57 relapsing multiple sclerosis 57 NYHA Class II 57 patients evaluable 57 CR CRu 57 Myelodysplastic Syndrome MDS 57 brand ciclesonide HFA 57 protease inhibitor PI 57 Newly Diagnosed Multiple Myeloma 57 DMARDs 57 differentiated thyroid 57 systemic lupus erythematosus SLE 57 trans retinoic acid ATRA 57 pertuzumab 57 cytarabine 57 chronic plaque psoriasis 57 relapsing remitting multiple sclerosis 57 Solid Tumors criteria 57 complete cytogenetic 57 histologically confirmed 57 leukemic 57 CTAP# Capsules 57 oblimersen 57 Acute Myeloid Leukemia AML 57 dacarbazine DTIC 57 Platinol ® cisplatin 57 TNF antagonists 57 MDS MPD 57 peripheral sensory neuropathy 57 lymphopenia 57 recurrent glioblastoma 57 phase Ph + 57 OMNARIS HFA 57 severe neutropenia 57 VAPRISOL 57 Glioblastoma multiforme GBM 57 cytopenias 57 EGFR mutation positive 57 dermatologic toxicities 57 T#I [002] 57 FOLFOX4 57 Leukemias 57 neoadjuvant 57 achieved sustained virological 57 mg BID 57 adult chronic ITP 57 metastatic hormone refractory 57 Doxil ® 57 Bronchiectasis 57 corticosteroid therapy 57 anti leukemic 57 refractory CLL 57 sunitinib Sutent 57 recurrent malignant glioma 57 relapsed Acute Myeloid 57 T2DM 57 heavily pretreated patients 57 hyperphenylalaninemia HPA due 57 PEGylated anti 57 Sapacitabine 57 cytotoxic chemotherapy 57 EGFR expressing mCRC 57 Ph + 57 severe exacerbations 57 refractory metastatic colorectal cancer 57 colorectal cancer liver metastases 57 Alemtuzumab 57 BCG refractory carcinoma 57 Ofatumumab 57 subependymal giant cell 57 virological failure 57 JAK2 V#F 57 immune thrombocytopenic purpura ITP 57 HBeAg negative 57 Aflibercept 57 SJIA 57 biliary tract cancer 57 PNP inhibitor 57 hematologic 57 biologic DMARD 57 Chronic Myelogenous Leukemia CML 57 5FU 57 adalimumab Humira 57 Pemetrexed 57 Annamycin 57 non squamous 57 phase IIb study 57 evaluable patients 57 Known hypersensitivity 57 systemic ALCL 57 evaluable subjects 57 chronic GVHD 57 pediatric malignancies 57 small lymphocytic lymphoma 57 dosage regimens 57 relapsed ovarian cancer 57 JAK1 57 non splenectomized 57 sorafenib tablets 57 sorafenib Nexavar 57 Dasatinib 57 PEGINTRON TM 57 interferon ribavirin 57 azacitidine 57 aHUS 56 HuLuc# 56 MabCampath 56 advanced hepatocellular carcinoma 56 Triapine 56 invasive aspergillosis 56 metastatic RCC 56 polycythemia vera essential thrombocythemia 56 LUX Lung 56 Omacetaxine mepesuccinate 56 TTR amyloidosis 56 TNF Tumor Necrosis Factor 56 ZOLINZA 56 HGS ETR2 56 nucleoside naive 56 underwent resection 56 lumiliximab 56 pediatric acute lymphoblastic 56 mapatumumab 56 doublet chemotherapy 56 relapsed multiple myeloma 56 Phase #b/#a clinical 56 hematologic malignancies 56 metastatic HRPC 56 HBeAg positive patients 56 drug DMARD 56 FUSILEV enhances 56 relapsing remitting MS RRMS 56 hepatorenal syndrome 56 systemic juvenile idiopathic 56 Brentuximab Vedotin SGN 56 5 fluorouracil leucovorin 56 GISTs 56 refractory acute myeloid 56 galiximab 56 treatment naive genotype 56 Gemzar ® 56 methotrexate MTX 56 plus prednisone prednisolone 56 Peginterferon alfa 2b 56 Flu Cy 56 evaluable 56 SinuNase TM 56 non metastatic resectable 56 Ph + CP 56 dexamethasone Decadron 56 FOLFIRI alone 56 acute leukemias 56 HCD# [002] 56 Monotherapy 56 paclitaxel cisplatin 56 dose cohort 56 Ceflatonin R 56 gemcitabine Gemzar 56 ANCA associated 56 REMICADE ® 56 Paraplatin ® 56 uric acid lowering 56 unresectable stage 56 receiving golimumab 56 paclitaxel poliglumex 56 HGS# 56 relapsed SCLC 56 interferon alfa 2b 56 RRMS patients 56 investigational oral inhibitor 56 curative resection 56 peritumoral brain edema 56 docetaxel Taxotere R 56 anaplastic astrocytoma AA 56 Chronic Lymphocytic Leukemia CLL 56 dirucotide MBP# 56 Phase 2b Clinical Trial 56 paclitaxel Taxol ® 56 risperidone Risperdal 56 delayed onset CINV 56 mRCC 56 sodium glucose cotransporter 56 Quinamed 56 achieved PASI 56 ALT flares 56 metastatic neuroendocrine tumors 56 plus COPEGUS 56 acyclovir Lauriad R 56 follicular NHL 56 Ceflatonin 56 ABVD 56 catheter occlusion 56 amrubicin 56 relapsing remitting MS 56 Hodgkin lymphoma HL 56 Tolvaptan 56 Vandetanib 56 dosing cohorts 56 trabectedin 56 anthracycline containing 56 LymphoStat B belimumab 56 low dose cytarabine 56 bevacizumab Avastin 56 surgical debulking 56 C1 INH deficiency 56 PegIFN RBV 56 relapsing remitting 56 MPS IVA 56 cyclophosphamide methotrexate 56 NOMID 56 adecatumumab 56 somatostatin analog 56 receiving INTRON 56 idiopathic thrombocytopenic purpura ITP 56 hepatocellular cancer 56 relapsed ALL 56 MAGE A3 ASCI 56 CANCIDAS 56 Vicinium TM 56 mycophenolate mofetil 56 Refractory Hodgkin Lymphoma 56 Traficet EN 56 relapsed refractory AML 56 vinorelbine 56 mg/m2 56 AGILECT R 56 FOLOTYN ® 56 Castration Resistant Prostate Cancer 56 temozolomide 56 taxane chemotherapy 56 HBeAg positive 56 medullary thyroid cancer 56 refractory ovarian cancer 56 amoxicillin clavulanate 56 opioid induced constipation OIC 56 Acute myeloid leukemia 56 grade cervical dysplasia 56 ulcerative colitis UC 56 DOXIL ® 56 non resectable 56 M2 subunit 56 HCV SPRINT 56 achieved sustained virologic 56 resectable 56 VELCADE melphalan 56 ARIKACE 56 Temsirolimus 56 mCRC 56 alpha interferons 56 pegylated interferon alpha 56 hormone refractory prostate cancer 56 tocilizumab 56 vinca alkaloid 56 T#I mutant 55 nasopharyngeal cancer 55 bone metastases 55 COU AA 55 assessing T DM1 55 phase IIb trial 55 ZACTIMA 55 Imatinib 55 Toxicities 55 dose regimens 55 gastrointestinal stromal tumor 55 recurrent glioma 55 grade cervical intraepithelial 55 BRIM2 55 mg administered orally 55 HCV protease 55 bortezomib Velcade 55 decitabine 55 relapsed leukemia 55 irinotecan doxorubicin oxaliplatin paclitaxel 55 metastatic NSCLC 55 histologic subtype 55 refractory gout 55 recurrent glioblastoma multiforme GBM 55 CA4P 55 diagnosed glioblastoma multiforme 55 multiple myeloma MM 55 cervical intraepithelial neoplasia 55 events AEs 55 generalized seizures 55 psoriatic arthritis PsA 55 pan HDAC inhibitor 55 adverse reactions incidence 55 mg/m2 administered 55 adalimumab 55 alpha folate receptor 55 hepatocellular carcinoma 55 hypophosphatemia 55 pegylated interferon alfa 55 eribulin 55 recurrent genital herpes 55 Gleevec imatinib mesylate 55 chronic idiopathic thrombocytopenic purpura 55 Hycamtin ® 55 chemotherapy docetaxel 55 hepatic metastases 55 RoACTEMRA 55 interferon alfa 2a 55 CLL SLL 55 Follicular Lymphoma 55 Chronic lymphocytic leukemia CLL 55 bosutinib 55 refractory multiple myeloma 55 ErbB2 positive 55 mg m² 55 cytarabine daunorubicin 55 OncoVEX GM CSF 55 hereditary deficiency 55 evaluating picoplatin 55 pediatric Crohn disease 55 carcinoma mCRC 55 elotuzumab 55 seliciclib 55 FOLFOX chemotherapy 55 Enzastaurin 55 ganetespib 55 VEGFR2 inhibitor 55 atypical hemolytic uremic syndrome 55 systemic fungal infections 55 progressive psoriatic arthritis 55 5-FU/LV 55 eribulin mesylate 55 TKI therapy 55 SPRYCEL 55 IAP inhibitor 55 CR nPR 55 VFEND 55 cyclophosphamide chemotherapy 55 Amigal 55 remission CR 55 anti EGFR antibody 55 pegfilgrastim 55 rituximab refractory 55 NATRECOR R 55 ® lenalidomide 55 metastatic colorectal 55 IMGN# 55 pegylated liposomal doxorubicin 55 BRAF mutations 55 systemic corticosteroid 55 cilengitide 55 Anthracycline 55 ELOXATIN 55 gastrointestinal stromal tumors GISTs 55 CRp 55 symptomatic BPH 55 blinded randomized placebo controlled 55 castration resistant prostate cancer 55 doxorubicin cyclophosphamide 55 axitinib 55 Panzem R NCD 55 allogeneic bone marrow 55 mycosis fungoides 55 Rheumatoid Arthritis RA 55 TMC# C# 55 KIT mutations 55 neurologic progression 55 administered subcutaneously 55 androgen independent 55 HBeAg negative patients 55 IMC A# 55 Telintra 55 ThermoDox ® 55 Navelbine ® 55 phase IIb clinical 55 myelodysplastic syndromes MDS 55 RECIST Response Evaluation Criteria 55 2 methoxyestradiol 55 5 FU 55 SAI EGF 55 pancreatic adenocarcinoma 55 CBLC# 55 Myelodysplastic Syndromes 55 relapsed acute myelogenous 55 Adjuvant chemotherapy 55 mg/m2/day 55 registrational Phase 55 Epratuzumab 55 Relapsing remitting MS 55 CIMZIA TM certolizumab pegol 55 huN# DM1 55 PsA 55 primary generalized tonic 55 refractory Hodgkin lymphoma 55 oral vancomycin 55 rALLy clinical trial 55 epithelial ovarian 55 paclitaxel Taxol 55 Trastuzumab 55 Paraplatin ® carboplatin 55 herpetic keratitis 55 rheumatoid arthritis psoriatic arthritis 55 trastuzumab Herceptin R 55 EGFR inhibitors 55 peginterferon alfa 2a 55 corticosteroids immunoglobulins 55 recurrent ovarian cancer 55 Chronic Lymphocytic Leukemia 55 infliximab therapy 55 anthracyclines taxanes 55 TRAIL R1 55 bortezomib 55 Acute lymphoblastic leukemia 55 #mg QD [002] 55 PREZISTA r 55 moderate ulcerative colitis 55 multicenter Phase III 55 YONDELIS 55 Stage IIB 55 Tarceva TM 55 plasma uric acid 55 HRPC 55 patients coinfected 55 mitoxantrone 55 severe renal impairment 55 liposomal doxorubicin 55 Cytarabine Liposome Injection 55 invasive candidiasis 55 iobenguane 55 placebo dexamethasone 55 taxane resistant 55 Cimzia TM 55 investigational humanized monoclonal antibody 55 hepatitis C genotype 55 DLTs 55 esophageal candidiasis 54 humanized anti 54 plus ribavirin 54 infliximab 54 operable breast cancer 54 de novo AML 54 riociguat 54 acute myelogenous leukemia AML 54 Phase 2a trial 54 antiangiogenesis therapies 54 toenail onychomycosis 54 acetonide FA 54 multi kinase inhibitor 54 bosentan 54 aggressive systemic mastocytosis 54 metastatic colorectal cancer 54 dose limiting toxicities 54 discontinuations due 54 targets EpCAM expressing 54 tumor necrosis 54 Glioblastoma Multiforme 54 myeloid metaplasia 54 alanine aminotransferase ALT 54 iniparib BSI 54 taxane therapy 54 LHRH analogues 54 APTIVUS r 54 postoperative chemotherapy 54 LHRH antagonists 54 dose escalation phase 54 INCB# [003] 54 lenalidomide dexamethasone 54 AMN# [001] 54 gemcitabine cisplatin 54 trastuzumab Herceptin ® 54 hA# 54 paclitaxel carboplatin 54 pemphigus vulgaris 54 teriflunomide 54 osteosarcoma Ewing sarcoma 54 Adalimumab 54 stage IIIB IV 54 allogeneic stem cell 54 Lymphocytic 54 humanized monoclonal antibody 54 myeloproliferative neoplasms 54 lupus erythematosus 54 oral prodrug 54 rALLy 54 dose cytarabine 54 epirubicin 54 xenograft models 54 NNRTI 54 intermittent dosing 54 SUTENT 54 soft tissue sarcomas 54 osteosarcomas 54 headache nasopharyngitis 54 oropharyngeal candidiasis OPC 54 fluoropyrimidine 54 cell carcinoma RCC 54 unresectable Stage III 54 topotecan 54 golimumab CNTO 54 adjunctive placebo 54 Raptiva ® 54 juvenile idiopathic arthritis 54 urinary N telopeptide 54 AML MDS 54 Voreloxin 54 anti rheumatic 54 AEG# 54 Hodgkin lymphoma NHL 54 gefitinib 54 KRAS mutant tumors 54 potentially hepatotoxic 54 ELACYT 54 myeloproliferative disorder 54 cell lymphoma ALCL 54 Uricase PEG 54 either acutely decompensated 54 MT# MEDI 54 cutaneous melanoma 54 unresectable recurrent 54 Azedra 54 DFMO 54 interferon alfa 54 LHON 54 sarcomatoid 54 splenectomized patients 54 Xyfid TM 54 serous ovarian cancer 54 aflibercept VEGF Trap 54 FOLPI regimen 54 Aplidin 54 Free Survival PFS 54 Tarceva erlotinib 54 fosbretabulin 54 NRTI resistance 54 microwave hyperthermia 54 Unstable Angina 54 astrocytomas 54 Campath alemtuzumab 54 BCG refractory 54 desvenlafaxine succinate 54 refractory 54 EGFR tyrosine kinase inhibitor 54 Vaprisol 54 dose escalation clinical 54 follicular lymphoma 54 brain tumor glioblastoma multiforme 54 external genital lesions 54 monotherapy 54 palifermin 54 cytopenia 54 Bayer HealthCare Onyx Pharmaceuticals 54 IV NSCLC 54 neovascular diseases 54 humanised monoclonal antibody 54 TELINTRA 54 metastatic gastric 54 solid tumors 54 ACTEMRA 54 luteinizing hormone releasing 54 TREANDA 54 6 mercaptopurine 54 nonmetastatic 54 icatibant 54 HSCT 54 evaluating REVLIMID 54 oral corticosteroid 54 Sudhir Agrawal D.Phil 54 nadolol 54 severe hypersensitivity reactions 54 Vidofludimus 54 virus HCV infection 54 HCV NS5B polymerase 54 HDAC Inhibitor 54 aripiprazole Abilify 54 colorectal carcinoma 54 locoregional 54 Jevtana 54 chemotherapeutic agent 54 metastatic renal 54 SAR# [004] 54 CAELYX 54 Malignant Melanoma 54 BRAF inhibitor 54 Archexin 54 taxane refractory 54 vWF 54 hematologic cancers 54 hematological 54 Idiopathic pulmonary fibrosis 54 etoposide 54 huC# DM4 54 prescribed proton pump 54 follicular non 54 Panzem R 54 SHPT 54 Retreatment 54 neoadjuvant chemotherapy 54 prednisone prednisolone 54 Curaxin CBLC# 54 colorectal liver metastases 54 Gefitinib 54 RRMS 54 GRASPA ® 54 sarcoma melanoma 54 acute coronary syndromes ACS 54 T1DM 54 MYLOTARG 54 Gorlin syndrome 54 Antitumor Activity 54 fluorouracil 54 mGluR5 NAM 54 TACE 54 Interferon alpha 54 primidone 54 mg kg dose 54 tyrosine kinase inhibitor 54 Acute Myeloid Leukaemia AML 54 azacytidine 54 proteasome inhibitor 54 seminoma 54 medically inoperable 54 radiochemotherapy 54 hematologic disorders 54 bortezomib refractory 54 Allovectin 7 54 anakinra 54 XL# SAR# 54 ofatumumab 54 prior chemotherapy regimen 53 Chronic Idiopathic Constipation 53 canakinumab 53 OADs 53 hematological cancers 53 juvenile idiopathic arthritis JIA 53 pegylated alpha interferon 53 indolent follicular non 53 FOLPI 53 YONDELIS R 53 NVA# 53 PI3K/Akt pathway inhibitor 53 mucosal healing 53 Idiopathic Pulmonary Fibrosis 53 PEG IFN 53 alefacept 53 nucleoside analogs 53 locoregional recurrence 53 Seliciclib 53 infusional 5-FU/LV 53 vascular disrupting agent 53 BEACOPP 53 chronic myelogenous leukemia 53 TTR gene 53 AQ4N 53 neoadjuvant treatment 53 generalized tonic clonic seizures 53 cyclophosphamide FC 53 thalidomide Thalomid 53 decompensated liver disease 53 INVANZ 53 Kinoid 53 OMAPRO 53 nonsmall cell lung cancer 53 oral methylnaltrexone 53 malignant gliomas 53 TYGACIL 53 Squamous 53 macroalbuminuria 53 oral ridaforolimus 53 dose cohorts 53 phase Ib 53 depsipeptide 53 refractory indolent non 53 Basal cell 53 pomalidomide 53 hyperoxaluria 53 comparator arm 53 neratinib 53 metastatic androgen independent 53 PegIFN 53 RECIST criteria 53 Phase 1b clinical 53 unresectable hepatocellular carcinoma HCC 53 calcineurin inhibitors 53 anticancer agents 53 hepatitis C HCV 53 Carboplatin 53 Herceptin trastuzumab 53 chemotherapeutic drug 53 chemo radiotherapy 53 Bortezomib 53 micafungin 53 HIV HCV coinfected 53 RAEB 53 fluoropyrimidine oxaliplatin 53 venlafaxine XR 53 velafermin 53 nonhematologic adverse reactions 53 Naive Patients 53 hormone refractory metastatic prostate 53 ascending doses 53 prostate cancer HRPC 53 anti arrhythmic drug 53 interferon therapy 53 lapatinib Tykerb 53 PROCTOCORT ® Suppository Hydrocortisone 53 IIIB NSCLC 53 relapsed myeloma